Grants Search Results

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Funding from the St. Baldrick's Foundation has taken two very small programs at UIC and Rush Medical Centers, merged them and brought Stroger Medical Center into the fold to forge a single entity for purposes of participation in Children's Oncology Group clinical trials. This support of necessary personnel has significantly increased clinical trial participation for patients who otherwise might not have access to them.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The grant is named in honor of the Do It for Dominic Fund. This Hero Fund was created in memory of Dominic Cairo, who died from Non-Hodgkin Lymphoma at the age of 8. His family and friends continue to focus their efforts on raising funds and supporting St. Baldrick’s in the effort find cures for childhood cancers in the hopes that no child ever has to go through what Dominic had to endure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant funds personnel to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Based on progress to date, Dr. Green was awarded a new grant in 2016 to fund an additional year of this Fellow award. High-grade gliomas (HGG) are brain tumors that are usually fatal in children. Dr. Green's work has recently shown promising results using a new medicine called Selinexor in laboratory models of HGG. Dr. Green, the Luke’s Army Pediatric Cancer Research Fund St. Baldrick’s Fellow, believes Selinexor works by restoring the function of proteins that suppress the tumor and acts as the brakes in cancer cells. Dr. Green's team is testing Selinexor for safety in children with various brain and solid tumors, and to see if it can extend survival.

A portion of this grant is named for the Luke's Army Pediatric Cancer Research Fund. Luke Ungerer brought smiles and sunshine wherever he went with plenty to share with everyone. He battled a brain tumor with a positive spirit and inspired others with his courage in his short life. This fund was created to carry on Luke’s legacy of positivity with the hope that it will ripple across many lives for many years to come. Awarded at Boston Children's Hospital and transferred to University of Colorado.

Based on progress to date, Dr. de Blank was awarded new grants in 2017 and 2018 to fund additional years of this Scholar award. Although therapies have improved for children with brain tumors, survival for malignant disease remains poor. Most of these children will have a recurrence of their tumor in the area of their original tumor, likely due to a tumor that was never fully removed. Dr. de Blank is investigating a new radiographic tool to diagnose brain tumors prior to surgery and define the extent of the tumor's invasion. This tool aims to improve outcomes by identifying children at risk for tumor recurrence and poor outcomes.

This project creates an international federation of experts in research and treatment of acute myeloid leukemia, an aggressive and frequently incurable blood cancer. The purpose is to integrate and share knowledge from real-time experiments that assess how the genetic alterations in leukemia cells influence response to therapies. Each patient's leukemia cells are profiled and physicians get the results in a rapid timeframe, which allows selection of treatments that have higher chances of benefit - this is called "precision" medicine. The know-how originated from this alliance will certainly advance the understanding of the disease and guide further investigation of promising drugs.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

This institution is a member of a research project which is being funded by St. Baldrick's: The AML Federation Project. For a description of this project, see the consortium grant made to the lead institution: Sage Bionetworks, Seattle, WA.

Langerhans cell histiocytosis (LCH) is a very rare type of neoplasm of the blood that has not been well investigated. It has been traditionally excluded from the major cooperative research groups, and thus considered an orphan disease. However, LCH affects many children. This consortium uses a uniform treatment while investigating the biology of the disease to seek for better therapeutic targets. Awarded at Dana-Farber Cancer Institute and transferred to St. Jude Children's Research Hospital. Funds administered by St. Jude Children's Research Hospital.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.

This institution is a member of a research consortium which is being funded by St. Baldrick's: North American Consortium for Histiocytosis (NACHO). For a description of this project, see the consortium grant made to the lead institution: St. Jude Children's Research Hospital, Memphis, TN.